Cary J Claiborne is Chief Executive Officer of ADIAL PHARMACEUTICALS, INC.. Currently has a direct ownership of 1.52 Million shares of ADIL, which is worth approximately $1.6 Million. The most recent transaction as insider was on May 23, 2023, when has been sold 420,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.52M
0% 3M change
0% 12M change
Total Value Held $1.6 Million

Cary J Claiborne Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 23 2023
BUY
Grant, award, or other acquisition
-
420,000 Added 21.65%
1,520,000 Common Stock
Sep 20 2022
BUY
Grant, award, or other acquisition
$31,500 $0.42 p/Share
75,000 Added 6.38%
1,100,000 Common Stock
Sep 19 2022
BUY
Grant, award, or other acquisition
$10,750 $0.43 p/Share
25,000 Added 2.38%
1,025,000 Common Stock
Aug 18 2022
BUY
Grant, award, or other acquisition
-
1,000,000 Added 50.0%
1,000,000 Common Stock

Also insider at

CYTR
CYTRX CORP Healthcare
CJC

Cary J Claiborne

Chief Executive Officer
Charlottesville, VA

Track Institutional and Insider Activities on ADIL

Follow ADIAL PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADIL shares.

Notify only if

Insider Trading

Get notified when an Adial Pharmaceuticals, Inc. insider buys or sells ADIL shares.

Notify only if

News

Receive news related to ADIAL PHARMACEUTICALS, INC.

Track Activities on ADIL